米诺环素辅助治疗早期精神分裂症阴性症状的双盲、随机、对照研究

A double-blind,randomized,controlled trial of minocycline combined with risperidone in the treatment of negative symptoms in early-phase schizophrenia

目的探讨米诺环素辅助治疗精神分裂症患者阴性症状的效果及耐受性。方法将92例符合《精神疾病诊断与统计手册》(DSM-IV)诊断标准、以阴性症状为主且单一利培酮治疗的精神分裂症患者随机分为米诺环素组(n=46)和安慰剂对照组(n=46),治疗周期为16周。于入组及出组时以阴性症状评定量表(SANS)、阳性和阴性症状量表(PANSS)评定疗效,使用静坐不能量表(Barnes)和锥体外系副反应量表(SAS)评定不良反应。结果米诺环素组在SANS分、PANSS阴性症状分、PANSS总分较安慰剂组相比,减分差异有统计学意义(P<0.01);两组间在副反应发生率及脱落率比较差异无统计学意义(P>0.05)。结论米诺环素可能有助于改善精神分裂症的阴性症状,且耐受性良好。

Objective Exploring the efficacy of minocycline combining with risperidone in the treatment of negative symptom of early - phase schizophrenia. Methods Ninety - two patients with early stage schizophrenia treated with risperidone were randomly as- signed to receive minoeycline or placebo. Two treatment group both take 16 - weeks. The clinical effect and adverse reactions were as- sessed with the Scale for the Assessment of Negative Symptoms （SANS） , the Positive and Negative Syndrome Scale （PANSS）, Barnes Akathisia Scale （Barnes） and Simpson Extrapyramidal Rating Scale （SAS） before the treatment and after. Results Subjects receiv- ing minocycline had greater improvements on SANS total scores, PANSS negative subscale scores and PANSS total score （ P 〈 0.01 ） when compared with those receiving placebo. Conclusion The addition of minocycline to atypical antipsychoticdrugs in early schizo- phrenia had significant efficacy on negative symptoms and had no serious side effect in patients with schizophrenia.